Chronic graft-versus-host disease: Disease biology and novel therapeutic strategies

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation. Chronic GVHD often presents with clinical manifestations that resemble those observed in autoimmune diseases. Standard treatment is 1-2mg/kg/day of prednisone or an equivalent dose of methylprednisolone, with continued administration of a calcineurin inhibitor for steroid sparing. However, the prognosis of steroid-refractory chronic GVHD remains poor. Classically, chronic GVHD was said to involve predominantly Th2 responses. We are now faced with a more complex picture, involving possible roles for thymic dysfunction, transforming growth factor-β (TGF-ß) and platelet-derived growth factor (PDGF), B cells and autoantibodies, and Th1/Th2/Th7 cytokines, as well as regulatory T cells (Tregs), in chronic GVHD. More detailed research on the pathophysiology of chronic GVHD may facilitate the establishment of novel strategies for its prevention and treatment.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalActa Medica Okayama
Volume67
Issue number1
Publication statusPublished - 2013

Fingerprint

Graft vs Host Disease
Grafts
Therapeutics
Steroids
Proto-Oncogene Proteins c-sis
Transplantation (surgical)
Hematopoietic Stem Cell Transplantation
Methylprednisolone
Transforming Growth Factors
Regulatory T-Lymphocytes
Prednisone
T-cells
Autoantibodies
Autoimmune Diseases
Stem cells
Refractory materials
B-Lymphocytes
Cytokines
Cells
Research

Keywords

  • Am80
  • Chronic GVHD
  • Regulatory T cell (Treg)
  • Steroid-refractory
  • Thl7

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Chronic graft-versus-host disease : Disease biology and novel therapeutic strategies. / Nishimori, Hisakazu; Maeda, Yoshinobu; Tanimoto, Mitsune.

In: Acta Medica Okayama, Vol. 67, No. 1, 2013, p. 1-8.

Research output: Contribution to journalArticle

@article{8376cc7e9db94932951a50c84e072798,
title = "Chronic graft-versus-host disease: Disease biology and novel therapeutic strategies",
abstract = "Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation. Chronic GVHD often presents with clinical manifestations that resemble those observed in autoimmune diseases. Standard treatment is 1-2mg/kg/day of prednisone or an equivalent dose of methylprednisolone, with continued administration of a calcineurin inhibitor for steroid sparing. However, the prognosis of steroid-refractory chronic GVHD remains poor. Classically, chronic GVHD was said to involve predominantly Th2 responses. We are now faced with a more complex picture, involving possible roles for thymic dysfunction, transforming growth factor-β (TGF-{\ss}) and platelet-derived growth factor (PDGF), B cells and autoantibodies, and Th1/Th2/Th7 cytokines, as well as regulatory T cells (Tregs), in chronic GVHD. More detailed research on the pathophysiology of chronic GVHD may facilitate the establishment of novel strategies for its prevention and treatment.",
keywords = "Am80, Chronic GVHD, Regulatory T cell (Treg), Steroid-refractory, Thl7",
author = "Hisakazu Nishimori and Yoshinobu Maeda and Mitsune Tanimoto",
year = "2013",
language = "English",
volume = "67",
pages = "1--8",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "1",

}

TY - JOUR

T1 - Chronic graft-versus-host disease

T2 - Disease biology and novel therapeutic strategies

AU - Nishimori, Hisakazu

AU - Maeda, Yoshinobu

AU - Tanimoto, Mitsune

PY - 2013

Y1 - 2013

N2 - Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation. Chronic GVHD often presents with clinical manifestations that resemble those observed in autoimmune diseases. Standard treatment is 1-2mg/kg/day of prednisone or an equivalent dose of methylprednisolone, with continued administration of a calcineurin inhibitor for steroid sparing. However, the prognosis of steroid-refractory chronic GVHD remains poor. Classically, chronic GVHD was said to involve predominantly Th2 responses. We are now faced with a more complex picture, involving possible roles for thymic dysfunction, transforming growth factor-β (TGF-ß) and platelet-derived growth factor (PDGF), B cells and autoantibodies, and Th1/Th2/Th7 cytokines, as well as regulatory T cells (Tregs), in chronic GVHD. More detailed research on the pathophysiology of chronic GVHD may facilitate the establishment of novel strategies for its prevention and treatment.

AB - Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation. Chronic GVHD often presents with clinical manifestations that resemble those observed in autoimmune diseases. Standard treatment is 1-2mg/kg/day of prednisone or an equivalent dose of methylprednisolone, with continued administration of a calcineurin inhibitor for steroid sparing. However, the prognosis of steroid-refractory chronic GVHD remains poor. Classically, chronic GVHD was said to involve predominantly Th2 responses. We are now faced with a more complex picture, involving possible roles for thymic dysfunction, transforming growth factor-β (TGF-ß) and platelet-derived growth factor (PDGF), B cells and autoantibodies, and Th1/Th2/Th7 cytokines, as well as regulatory T cells (Tregs), in chronic GVHD. More detailed research on the pathophysiology of chronic GVHD may facilitate the establishment of novel strategies for its prevention and treatment.

KW - Am80

KW - Chronic GVHD

KW - Regulatory T cell (Treg)

KW - Steroid-refractory

KW - Thl7

UR - http://www.scopus.com/inward/record.url?scp=84875852566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875852566&partnerID=8YFLogxK

M3 - Article

C2 - 23439503

AN - SCOPUS:84875852566

VL - 67

SP - 1

EP - 8

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 1

ER -